In this review, we summarize and discuss the current state-of-the-art knowledge regarding the potential of human Vδ2 T cells to be used in cancer immunotherapy with a focus on the NKG2A immune checkpoint (IC) in order to emphasize its importance and potential in the development of new IC-based therapeutic approaches in the near future. This evidence concerns the gene KLRC1 and cancer.